
Sign up to save your podcasts
Or


On this episode of Stock Movers:
- ABB Ltd. rallied after the company reported record order intake and profit margins that surpassed views, spurred by rising demand for automation tools and data center-driven investments in electrical grids. Orders surged 16% in the second quarter to $9.79 billion, lifted by a single $600 million deal for process-automation tools in the US, the Zurich-based industrial supplier said Thursday in a statement. ABB shares gained as much as 8.5%, the most intraday in over three months.
- Legrand shares are trading at a record high this morning after jumping as much as 8.4% as the electrical device specialist posted organic growth well ahead of expectations in the second quarter and raised its outlook for the full year. Analysts cited strong demand for data centers in North America.
- Novartis AG slumped after disappointing sales for its key psoriasis drug and the looming retirement of its respected finance chief overshadowed a modest outlook raise. Core operating profit will likely grow by a percentage in the low teens, the Swiss drugmaker said Thursday. New medicines made up for lackluster growth from the psoriasis treatment Cosentyx, which analysts pointed to as a concern. The shares fell as much as 2.8% in early Zurich trading, trimming this year’s gain to about 5%.
See omnystudio.com/listener for privacy information.
By iHeartPodcasts4.6
1919 ratings
On this episode of Stock Movers:
- ABB Ltd. rallied after the company reported record order intake and profit margins that surpassed views, spurred by rising demand for automation tools and data center-driven investments in electrical grids. Orders surged 16% in the second quarter to $9.79 billion, lifted by a single $600 million deal for process-automation tools in the US, the Zurich-based industrial supplier said Thursday in a statement. ABB shares gained as much as 8.5%, the most intraday in over three months.
- Legrand shares are trading at a record high this morning after jumping as much as 8.4% as the electrical device specialist posted organic growth well ahead of expectations in the second quarter and raised its outlook for the full year. Analysts cited strong demand for data centers in North America.
- Novartis AG slumped after disappointing sales for its key psoriasis drug and the looming retirement of its respected finance chief overshadowed a modest outlook raise. Core operating profit will likely grow by a percentage in the low teens, the Swiss drugmaker said Thursday. New medicines made up for lackluster growth from the psoriasis treatment Cosentyx, which analysts pointed to as a concern. The shares fell as much as 2.8% in early Zurich trading, trimming this year’s gain to about 5%.
See omnystudio.com/listener for privacy information.

406 Listeners

1,173 Listeners

2,175 Listeners

1,993 Listeners

427 Listeners

1,044 Listeners

1,320 Listeners

65 Listeners

64 Listeners

155 Listeners

87 Listeners

80 Listeners

81 Listeners

9 Listeners

11 Listeners